# US 2026/0116859 A1 · Charged Ion Channel Blockers and Methods for Use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0116859 A1
- Document ID: US20260116859A1
- Status: Published application
- Kind: A1
- Application number: 19/231,962
- Filed: 2025-06-09
- Published: 2026-04-30
- Earliest claimed: 2019-03-11
- Assignees: Nocion Therapeutics, Inc.
- Applicants: Nocion Therapeutics, Inc.
- Inventors: Bridget McCarthy COLE; James Lamond ELLIS
- Web page: https://patentgrep.com/patent/US20260116859A1

## CPC

- C07D 241/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A61P 11/14: Antitussive agents
- A61P 17/04: Antipruritics
- A61P 25/00: Drugs for disorders of the nervous system
- C07D 213/04: having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D 213/26: Radicals substituted by halogen atoms or nitro radicals
- C07D 213/56: Amides
- C07D 213/61: Halogen atoms or nitro radicals
- C07D 213/65: attached in position 3 or 5
- C07D 213/71: to which a second hetero atom is attached
- C07D 213/73: Unsubstituted amino or imino radicals
- C07D 213/74: Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C07D 213/75: Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
- C07D 213/82: in position 3
- C07D 213/85: in position 3
- C07D 215/10: Quaternary compounds
- C07D 217/10: Quaternary compounds
- C07D 217/22: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 231/14: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 231/56: Benzopyrazoles; Hydrogenated benzopyrazoles
- C07D 233/61: with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
- C07D 233/64: with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- C07D 233/90: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 237/08: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 471/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof: The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, cough, itch, and neurogenic inflammation.

## Claims

### Claim 1

A compound represented by Formula (I)
wherein:
Y− is a pharmaceutically acceptable anion;
RF and RG together with the N+ to which they are attached form an optionally substituted heteroaryl ring having zero, one or more heteroatoms in addition to the N+, or an optionally substituted bicyclic heteroaryl ring having zero, one or more heteroatoms in addition to the N+;
RA, RB, and RC are each independently selected from H, D halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, nitrile, ORI, NRJRK, NRLC(O)RM, S(O)RN, SO2RO, SO2RORP, SO2NRQRR, SO3RS, CO2RT, C(O)RU, and C(O)NRVRW; or RB and vicinal RC together with the carbon atoms to which they are attached form a substituted or unsubstituted 3-7-membered cycloalkyl or a substituted or unsubstituted aryl;
each of RI, RJ, RK, RL, RM, RN, RO, RP, RQ, RR, RS, RT, RU, RV, and RW is independently selected from H, D, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl;
X1 is selected from —CRXRY—, —NRZC(O)—, —NRZC(O)CRXRY—, —OC(O)—, —SC(O)—, —C(O)NR1A—, —C(O)O—, —NRZS(O)—, —S(O)NRZ—, —NRXC(O)NRY—, —(O)CS—, —C(O)—, —S(O)—, and —S(O)2—;
each of RX, RY, RZ, and R1A is independently selected from H, D, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl; and
each of RD and RE is independently selected from H, D, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, cycloalkyl, aryl, or heteroaryl; or RD and RE together with the carbon to which they are attached form a substituted or unsubstituted C3-C7 cycloalkyl or a substituted or unsubstituted heterocyclic ring; or RD and RZ together with the carbon and the —N—C(O)— to which they are attached form an optionally substituted 5-8-membered lactam.

### Claim 2 (depends on 1)

The compound of claim 1, wherein Y− is iodide, bromide, or chloride.

### Claim 3 (depends on 1)

The compound of claim 1, wherein X1 is —NHC(O)—.

### Claim 4 (depends on 1)

The compound of claim 1, wherein each of RA and RB is independently selected from H, D, nitrile, halogen, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, and NRJRK; and each of RJ and RK is independently selected from H, substituted or unsubstituted C1-4 alkyl, substituted or unsubstituted C2-4 alkenyl, and substituted or unsubstituted C2-4 alkynyl.

### Claim 5 (depends on 1)

The compound of claim 1, wherein RA, RB, and RC are each independently selected from H, D, halogen, ORI, substituted or unsubstituted C1-C4 alkyl, and NRJRK; wherein each of RI, RJ and RK is independently selected from H and substituted or unsubstituted C1-C4 alkyl.

### Claim 6 (depends on 1)

The compound of claim 1, wherein each of RA and RB is CH3, and RC is selected from the group consisting of H, CH3, halogen, nitrile, methoxy, and ethoxy.

### Claim 7 (depends on 1)

The compound of claim 1, wherein RD is C1-4 alkyl optionally substituted with a substituent selected from the group consisting of halogen, oxygen, C3-8 cyclic alkyl, aryl, and heteroaryl.

### Claim 8 (depends on 1)

The compound of claim 1, wherein RE is H, D, or C1-4 alkyl optionally substituted with a substituent selected from the group consisting of halogen, oxygen, C3-8 cyclic alkyl, aryl, and heteroaryl.

### Claim 9 (depends on 1)

The compound of claim 1, wherein RD and RE are both hydrogen.

### Claim 10 (depends on 1)

The compound of claim 1, wherein RD is hydrogen and RE is an C1-C6 alkyl.

### Claim 11 (depends on 1)

The compound of claim 1, wherein RD and RE are taken together with the carbon to which they are attached to form a C3-C6 cycloalkyl including, but not limited to, cyclopropyl and cyclobutyl.

### Claim 12 (depends on 1)

The compound of claim 1, wherein RF and RG together with the N+ form an optionally substituted heteroaryl ring or an optionally substituted bicyclic heteroaryl ring comprising one or more heteroatoms selected from the following:

### Claim 13 (depends on 1)

The compound of claim 1, wherein RF and RG together with the N+ form an optionally substituted pyridinium ring.

### Claim 14 (depends on 1)

The compound of claim 1, wherein the heteroaryl ring or bicyclic heteroaryl ring formed by RF and RG together is optionally substituted with a substituent selected from the group consisting of substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted and unsubstituted 3- to 15-membered heterocyclyl, alkoxy, or CO2R2A, wherein R2A is selected from H, D, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl.

### Claim 15 (depends on 1)

The compound of claim 1, wherein the compound is selected from those below:
Compound
Chemical Structure
Compound 1
Compound 2
Compound 3
Compound 4
Compound 5
Compound 6
Compound 7
Compound 8
Compound 9
Compound 10
Compound 11
Compound 12
Compound 13
Compound 14
Compound 15
Compound 16
Compound 17
Compound 18
Compound 19
Compound 20
Compound 21
Compound 22
Compound 23
Compound 24
Compound 25
Compound 26
Compound 27
Compound 28
Compound 29
Compound 30
Compound 31
Compound 32
Compound 33
Compound 34
Compound 35
Compound 36
Compound 37
Compound 38
Compound 39
Compound 40
Compound 41
Compound 42
Compound 43
Compound 44
Compound 45
Compound 46
Compound 47
Compound 48
Compound 49
Compound 50
Compound 51
Compound 52
Compound 53
Compound 54
Compound 55
Compound 56
Compound 57
Compound 58
Compound 59
Compound 60
Compound 61
Compound 62
Compound 63
Compound 64
Compound 65
Compound 66
Compound 67
Compound 68
Compound 69
Compound 70
Compound 71
Compound 72
Compound 73
Compound 74
Compound 75
Compound 76
Compound 77
Compound 78
Compound 79
Compound 80
Compound 81
Compound 82
Compound 83
Compound 84
Compound 85
Compound 86
Compound 87
Compound 88
Compound 89
Compound 90
Compound 91
Compound 92
Compound 93
Compound 94
Compound 95
Compound 96
Compound 97
Compound 98
Compound 99
Compound 100
Compound 101
Compound 102
Compound 103
Compound 104
Compound 105
Compound 106
Compound 107
Compound 108
Compound 109
Compound 110
Compound 111
Compound 112
Compound 113
Compound 114
Compound 115
Compound 116
Compound 117
Compound 118
Compound 119
Compound 120
Compound 121
Compound 122
Compound 123
Compound 124
Compound 125
Compound 126
Compound 127
Compound 128
Compound 129

### Claim 16 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

### Claim 17 (depends on 16)

The composition of claim 16, wherein said composition is formulated for oral, intravenous, intramuscular, rectal, cutaneous, subcutaneous, topical, transdermal, sublingual, nasal, inhalation, vaginal, intrathecal, epidural, or ocular administration.

### Claim 18 (depends on 1)

A method for treating pain, cough, itch, or a neurogenic inflammatory disorder in a patient, comprising administering to said patient an effective of a compound of claim 1.

### Claim 19 (depends on 18)

The method of claim 18, wherein said pain is selected from the group consisting of pain due to back and neck pain, lower back pain, cancer pain, gynecological and labor pain, fibromyalgia, arthritis, rheumatoid arthritis, osteoarthritis, rheumatological pains, orthopedic pains, acute and post herpetic neuralgia and other neuropathic pains (including peripheral neuropathy), sickle cell crises, vulvodynia, peri-anal pain, irritable bowel disease, irritable bowel syndrome, inflammatory bowel disease, oral mucositis, esophagitis, interstitial cystitis, urethritis and other urological pains, dental pain, headaches, trigeminal trophic syndrome, erythromelalgia, abdominal wall pain, chronic abdominal wall pain, allergic rhinitis, muscle pain, rectal pain, Levator ani syndrome, proctalgia fugax, hemorrhoid pain, stomach pain, skin ulcers, stomach ulcers, burn pain, ophthalmic irritation, conjunctivitis (e.g., allergic conjunctivitis), eye redness, dry eye, dry eye syndrome (chronic ocular pain), complex regional pain syndrome, post-surgical ocular pain, postoperative pain, acute postoperative pain, and procedural pain (i.e., pain associated with injections, draining an abscess, surgery, dental procedures, ophthalmic procedures, arthroscopies and use of other medical instrumentation, cosmetic surgical procedures, dermatological procedures, setting fractures, biopsies, and the like).

### Claim 20 (depends on 18)

The method of claim 18, wherein said cough is selected from the group consisting of cough in patients with asthma, COPD, asthma-COPD overlap syndrome (ACOS), interstitial pulmonary fibrosis (IPF), idiopathic pulmonary fibrosis, post viral cough, post-infection cough, chronic idiopathic cough and lung cancer.

### Claim 21 (depends on 18)

The method of claim 18, wherein said itch is selected from the group consisting of itch due to pruritus, brachioradial pruritus, chronic idiopathic pruritus, genital/anal pruritus, notalgia paresthetica, scalp pruritus, allergic dermatitis, contact dermatitis, atopic dermatitis, hand eczema, poison ivy, infections, parasites, insect bites, pregnancy, metabolic disorders, liver or renal failure, drug reactions, allergic reactions, eczema, genital and anal itch, hemorrhoid itch, and cancer.

### Claim 22 (depends on 18)

The method of claim 18, wherein said neurogenic inflammatory disorder is selected from the group consisting of allergic inflammation, asthma, chronic cough, conjunctivitis, rhinitis, psoriasis, inflammatory bowel disease, interstitial cystitis, arthritis, colitis, contact dermatitis, diabetes, eczema, cystitis, gastritis, migraine headache, rosacea, sunburn, pancreatitis, chronic rhinosinusitis, traumatic brain injury, polymicrobial sepsis, tendinopathies, chronic urticaria, rheumatic disease, acute lung injury, exposure to irritants, inhalation of irritants, pollutants, chemical warfare agents, and atopic dermatitis.

### Claim 23 (depends on 18)

The method of claim 18, wherein a compound represented by Formula (I) is used in combination with one or more exogenous large pore receptor agonists.
